MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) today announced the acquisition of two privately held companies, Biogenesis Ltd. (Poole/U.K.) and Biogenesis Inc. (Brentwood, New Hampshire/U.S.A.). The Biogenesis Group represents one of the larger European suppliers of antibodies to the life sciences research community, and combined with MorphoSys’ existing efforts in this area, the acquisition will establish MorphoSys as one of the top 5 European suppliers of research antibodies. The final agreements, signed on January 20, 2005, specify the purchase of 100% ownership of Biogenesis Ltd. and Biogenesis Inc. by MorphoSys for GBP 5.25 million, less net debt of approximately GBP 700,000, in cash. The two Biogenesis companies will become wholly owned subsidiaries of MorphoSys AG. The new unit will run alongside the existing therapeutic antibodies unit, which comprises the largest part of the MorphoSys business.